PMID- 22613597
OWN - NLM
STAT- MEDLINE
DCOM- 20120921
LR  - 20131121
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 125
IP  - 7
DP  - 2012 Apr
TI  - Impact of surgery and epirubicin intravesical chemotherapy on peripheral blood 
      dendritic cell subsets in patients with superficial urothelial carcinoma of the 
      bladder.
PG  - 1254-60
AB  - BACKGROUND: Superficial urothelial carcinoma (SUC) of the bladder is a common 
      urinary tract tumor in China. There is a high recurrence rate of this tumor even 
      after surgery and intravesical instillation. Previous reports have described a 
      suppression of the immune system in cancer patients. Dendritic cells (DCs) play a 
      pivotal role in the induction of an effective antitumor immune response. The aim 
      of this study was to investigate the effects of surgery and epirubicin 
      intravesical chemotherapy (IC) on peripheral blood DCs in subsets of patients 
      with bladder SUC. METHODS: A total of 66 SUC patients and 38 healthy controls 
      were enrolled in this study. All the patients had undergone transurethral 
      resection (TUR) of their cancer and adjunctive IC after tumor removal. The 
      patients were divided into a non-recurrence group (n = 40) and a recurrence group 
      (n = 26) based on the presence or absence of tumor recurrence. Blood samples were 
      taken preoperatively (PreOP), on postoperative days (POD) 1 and 7, and at 
      postoperative month (POM) 3. Flow cytometric analysis was used for the 
      determination and quantitation of the surface markers CD80 and CD86 in 
      circulating DC subsets. RESULTS: The preoperative percentages of myeloid 
      dendritic cells (mDCs) and expression of CD80 and CD86 were impaired in SUC 
      patients compared to healthy controls (P < 0.05). The percentages of mDCs and 
      these surface markers decreased significantly on POD 1 and increased on POD 7, 
      remaining higher than the preoperative values in POM 3 (P < 0.05). The 
      percentages of mDCs, and CD80 and CD86 in the non-recurrence group on PreOP, POD 
      7, and POM 3 were higher than those in recurrence group. CONCLUSIONS: Surgical 
      removal of SUC and adjunctive IC were associated with improved circulating mDC 
      counts and function. Persistent depression of mDC counts and function after 
      treatment in recurrence patients indicated lower antitumor immunity that may lead 
      to tumor recurrence.
FAU - Feng, Lang
AU  - Feng L
AD  - Department of Urology, Beijing Friendship Hospital, Capital Medical University, 
      Beijing, China.
FAU - Ma, Lin-lin
AU  - Ma LL
FAU - Zhang, Yu-hai
AU  - Zhang YH
FAU - Tian, Ye
AU  - Tian Y
FAU - Qu, Chen-xue
AU  - Qu CX
FAU - Wang, Yang
AU  - Wang Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 3Z8479ZZ5X (Epirubicin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - China
MH  - Dendritic Cells/immunology/*metabolism
MH  - Epirubicin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Urinary Bladder Neoplasms/*drug therapy/*immunology/*surgery
EDAT- 2012/05/23 06:00
MHDA- 2012/09/22 06:00
CRDT- 2012/05/23 06:00
PHST- 2012/05/23 06:00 [entrez]
PHST- 2012/05/23 06:00 [pubmed]
PHST- 2012/09/22 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2012 Apr;125(7):1254-60.